SciClone Pharmaceuticals Inc
Bokang Zhou is an accomplished professional with extensive experience in commercial operations and leadership roles within the pharmaceutical and medical industries. Currently, Bokang holds the position of Director of Commerce at NovaMed and serves as Vice President of Commerce at SciClone Pharmaceuticals since May 2008. Prior experience includes serving as VP of Commercial Operations at SCLN Co., Ltd. from June 2011 to July 2013, and as Head of Commercial Operation at B.Braun Medical Ltd from April 2007 to April 2008. Additionally, Bokang was a Regional Manager at AstraZeneca from August 2003 to April 2007, demonstrating a strong background in strategic management and operational excellence.
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.